ZOCOR
What it isHMG-CoA reductase inhibitor for hyperlipidemia and ASCVD prevention; a moderate-intensity statin.
Why this oneIts low cost and long familiarity are offset by more CYP3A4 restrictions than nearly any other statin.
What limits itStrong CYP3A4 inhibitors can precipitate myopathy; common cardiovascular drugs impose dose ceilings. Take it in the evening.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hyperlipidemia | Adults | 20 mg | 20–40 mg | 40 mg (80 mg QD only if tolerated chronically ≥12 mo) |
| HeFH | Pediatric ≥10 yr | 10 mg | 10–40 mg | 40 mg |
Renal Severe impairment (CLcr 15–29): start 5 mg QD; no adjustment for mild–moderate
Hepatic Contraindicated in acute liver failure or decompensated cirrhosis
Pregnancy May cause fetal harm; discontinue when pregnancy is recognized
Lactation Breastfeeding not recommended during treatment
NO BOXED WARNINGS
Principal riskMyopathy, dose-related and worsened by CYP3A4 inhibitors
Cost, est. cash$4–$80/month
Generic entry2006
Legacy pregnancy categoryX
Defining liabilityMyopathy/rhabdomyolysis and hepatotoxicity; interaction burden varies by agent.

Open Simvastatin in the interactive console ↗
